rs6003
| Orientation | minus |
| Stabilized | minus |
| Geno | Mag | Summary |
|---|---|---|
| (T;T) | 0 |
| Make rs6003(A;A) |
| Make rs6003(A;G) |
| Make rs6003(G;G) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 1 |
| Position | 197061891 |
| Gene | F13B |
| is a | snp |
| is | mentioned by |
| dbSNP | rs6003 |
| dbSNP (classic) | rs6003 |
| ClinGen | rs6003 |
| ebi | rs6003 |
| HLI | rs6003 |
| Exac | rs6003 |
| Gnomad | rs6003 |
| Varsome | rs6003 |
| LitVar | rs6003 |
| Map | rs6003 |
| PheGenI | rs6003 |
| Biobank | rs6003 |
| 1000 genomes | rs6003 |
| hgdp | rs6003 |
| ensembl | rs6003 |
| geneview | rs6003 |
| scholar | rs6003 |
| rs6003 | |
| pharmgkb | rs6003 |
| gwascentral | rs6003 |
| openSNP | rs6003 |
| 23andMe | rs6003 |
| SNPshot | rs6003 |
| SNPdbe | rs6003 |
| MSV3d | rs6003 |
| GWAS Ctlg | rs6003 |
| GMAF | 0.1938 |
| Max Magnitude | 0 |
| ? | (A;A) (A;G) (G;G) | 28 |
|---|---|---|
|
| ||
| ClinVar | |
|---|---|
| Risk | rs6003(A;A) |
| Alt | rs6003(A;A) |
| Reference | rs6003(G;G) |
| Significance | Other |
| Disease | Venous thrombosis not specified Factor xiii |
| Variation | info |
| Gene | F13B |
| CLNDBN | Venous thrombosis, susceptibility to not specified Factor xiii, b subunit, deficiency of |
| Reversed | 1 |
| HGVS | NC_000001.10:g.197031021C>T |
| CLNSRC | OMIM Allelic Variant UniProtKB (protein) |
| CLNACC | RCV000017984.2, RCV000253350.1, RCV000301691.1, |
[PMID 15660291
] Population structure, admixture, and aging-related phenotypes in African American adults: the Cardiovascular Health Study.
[PMID 18541031] The NEI/NCBI dbGAP database: genotypes and haplotypes that may specifically predispose to risk of neovascular age-related macular degeneration.
[PMID 18654799] Exploration of the utility of ancestry informative markers for genetic association studies of African Americans with type 2 diabetes and end stage renal disease.
[PMID 20021678] Evaluation of self-reported ethnicity in a case-control population: the stroke prevention in young women study.
[PMID 23582991] Genetic Influences on the Outcome of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-related Macular Degeneration
